Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020PRNewsWire • 10/21/20
Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 PneumoniaPRNewsWire • 08/18/20
Vanda Pharmaceuticals Is Still Undervalued Despite Strong Performance During The PandemicSeeking Alpha • 08/12/20
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/06/20
FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis SyndromePRNewsWire • 08/03/20
Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020PRNewsWire • 07/29/20
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 07/22/20
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA)Business Wire • 07/21/20
FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesisPRNewsWire • 07/13/20
Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and RemdesivirPRNewsWire • 05/20/20
This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19The Motley Fool • 05/14/20
Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/07/20
Vanda Begins Enrollment in Study for Severe Coronavirus InfectionZacks Investment Research • 04/16/20
Vanda Pharmaceuticals' (VNDA) CEO Mihales Polymeropoulos on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20